AzTrials
AzTrials

AgeingBLINDSCENCT06863727

The Beijing Longitudinal Disability Survey in Community Elderly

An observational study of Ageing and Disability, run by Xuanwu Hospital, Beijing at 1 site in China.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this observational study is to establish the prospective cohort of the Beijing Longitudinal Disability Survey in Community Elderly (BLINDSCE) to explore the high-risk factors and preventive interventions for disability and cognitive impairment among community-dwelling adults aged 65 years and over. Read more about this study

Who is it for?
Ages 65 years and olderHealthy volunteers can take part
Conditions the study is for
Ageing, Disability, Cognitive Impairment
How many people
1,962 participants
Where
1 siteChina
Study dates
7 Aug 2023to 31 Jul 2028
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 65 years and older
  • All sexes
  • Healthy volunteers accepted
  • Older adult

Study population: Community residents aged 65 years or older in Beijing

Who may be able to join

  • Community-dwelling adults aged 65 years or older who reside in Beijing.
  • Participants who sign an institutionally approved informed consent.

Who cannot join

  • Participants with severe mental disorders and serious medical conditions preventing study investigation
  • Participants undergoing long-term professional treatment for physical function and cognitive functioning, such as hospitalization or rehabilitation.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Yansu Guo, Ph.D contact

0086031183973736

gys188@163.com

China1 site, 1 recruiting

  • Xuanwu Hospital, Capital Medical University

    Beijing, 100053

    Yansu Guo, Ph.D, 0086031183973736, gys188@163.com

    Recruiting

Other trials in China

About this study

The goal of this observational study is to establish the prospective cohort of the Beijing Longitudinal Disability Survey in Community Elderly (BLINDSCE) to explore the high-risk factors and preventive interventions for disability and cognitive impairment among community-dwelling adults aged 65 years and over. The main question it aims to answer is:

  • What are the high-risk factors able to predict the incidence and advance of disability and cognitive impairment in community-dwelling adults aged 65 years and over?
  • What are the categories of function and cognitive performance trajectory in community-dwelling adults aged 65 years and over?
Read the detailed description

BLINDSCE is a community-based prospective cohort study that includes individuals aged 65 and over from urban and rural areas in Beijing. Participants will provide detailed demographic information and undergo multifactorial questionnaires, disability measurements, cognitive assessments, other disability-related outcomes, and clinical biochemical measures. The study has started recruitment and enrollment in 2023 and will follow-up once every 1-2 year. This work consists of three steps as follows. First, by collecting baseline and follow-up data of participants, we plan to establish a community-dwelling elderly database in Beijing. Second, high-risk factors can be pre-screening based on this cross-sectional analysis. Third, longitudinal data was used to develop the prediction model and trajectory analysis for disability and cognitive impairment.

Keywords
Ageing, Disability, Cognitive Impairment, Community, Cohort
Medical subject headings
Cognitive Dysfunction, Frailty

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Disability from the individual's perspective

    Disability is assessed using the 12-item World Health Organization's Disability Assessment Schedule 2.0 (WHODAS 2.0). The WHODAS 2.0 is a patient-reported disability measure, comprising six life domains involving cognition, mobility, self-care, interpersonal relationships, life activities, and participation. The total score of 12-item WHODAS 2.0 categorizes disability from no disability (score 0) to complete disability (score 48).

    Measured: An average of 1 to 2 years

  2. Disability from the medical's perspective

    Disability is assessed using the basic activities of daily living (BADL) scale, the Katz Index scale. The minimum value is 0 , and the maximum value is 6. The higher the score, the better the outcome.

    Measured: An average of 1 to 2 years

  3. Disability from the medical's perspective

    Disability is assessed using the instrumental activities of daily living (IADL) scale, the Lawton and Brody IADL scale. The minimum value is 0, and the maximum value is 8. The higher the score, the better the outcome.

    Measured: An average of 1 to 2 years

Secondary outcomes (13)

  1. Cognitive impairment

    The cognitive impairment is assessed by the Mini-Mental State Examination (MMSE). The minimum value is 0, and the maximum value is 30. The higher the score, the better the outcome.

    Measured: An average of 1 to 2 years

  2. Cognitive impairment

    The cognitive impairment is assessed by the Montreal Cognitive Assessment-Basic (MoCA-B). The minimum value is 0, and the maximum value is 30. The higher the score, the better the outcome.

    Measured: An average of 1 to 2 years

  3. Subjective cognitive decline

    Subjective cognitive decline is assessed by the subjective cognitive decline questionnaire-9 items (SCD9). The minimum value of SCD9 is 0, and the maximum value is 9, the higher the score, the worse the outcome.

    Measured: An average of 1 to 2 years

  4. Intrinsic capacity

    Intrinsic capacity is the composite of physical and mental abilities that an individual can draw upon. It comprises locomotor, sensory (hearing and vision), vitality, psychological, and cognition domains. The intrinsic capacity composite score is used to assess intrinsic capacity. The intrinsic capacity composite score ranges from 0 to 100, and the higher the score, the better the outcome.

    Measured: An average of 1 to 2 years

  5. Intrinsic capacity

    Intrinsic capacity is assessed by the integrated care for older people (ICOPE) scale. The minimum value of the ICOPE score is 0, and the maximum value is 5, the higher the score, the better the outcome.

    Measured: An average of 1 to 2 years

  6. Frailty

    Frailty is assessed using the Fried frailty phenotype (FFP) scale. The minimum value is 0, and the maximum value is 5. The higher the score, the worse the outcome.

    Measured: An average of 1 to 2 years

  7. Hospitalization

    Hospitalized times, duration, diagnosis, surgery, bedridden status, assisted ventilation treatment, catheter treatment are collected by questionnaire and supplemented through a review of electronic medical records.

    Measured: An average of 1 to 2 years

  8. Death

    The date and cause of death are collected from the participant's family members/healthcare providers and supplemented through a review of electronic medical records.

    Measured: An average of 1 to 2 years

  9. Appendicular skeletal muscle mass

    Appendicular skeletal muscle mass (ASM) is estimated using a physical measurement formula. Weight in kilograms, height in centimeters, gender(male or female), and age in years are combined to report ASM through the formula: ASM = 0.193*weight(kg) + 0.107*height(cm) - 4.157 * gender - 0.037*age(year) - 2.631. The higher the value, the better the outcome.

    Measured: An average of 1 to 2 years

  10. Muscle strength

    Muscle strength is assessed by the grip strength. The higher the value, the better the outcome.

    Measured: An average of 1 to 2 years

  11. Physical performance

    Physical performance is assessed by the Short Physical Performance Battery (SPPB) test. The minimum score is 0, and the maximum score is 12. The higher the score, the better the outcome.

    Measured: An average of 1 to 2 years

  12. Sarcopenia

    Sarcopenia is screened by the SARC-F scale. The minimum value is 0, and the maximum value is 10. The higher the score, the worse the outcome.

    Measured: An average of 1 to 2 years

  13. Sarcopenia

    Sarcopenia is assessed based on the criteria recommended by the Asian Working Group for Sarcopenia (AWGS) 2019 consensus, including muscle strength, plus appendicular skeletal muscle mass (ASM), and/or physical performance. AWGS 2019 contends that diagnosing sarcopenia requires both low muscle strength and muscle mass, and defines persons with low muscle mass, low muscle strength, and low physical performance as having "severe sarcopenia."

    Measured: An average of 1 to 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Mar 2025
  2. Study start7 Aug 2023
  3. Primary completion31 Jul 2028 (estimated)
  4. Study completion31 Jul 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
1,962 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06863727
Sponsor's protocol ID
No.[2023]129
Other IDs
2024-2G-20112
Acronym
BLINDSCE
Status last verified
Mar 2025
First submitted
16 Feb 2025
Last updated
7 Mar 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Cheng S, Du X, Hou C, Liu H, Lei S, Wu Y, Yue X, Guo Y. Beijing Longitudinal Disability Survey in Community Elderly (BLINDSCE): protocol for a community-based prospective longitudinal cohort study about disability prediction model. BMJ Open. 2025 May 15;15(5):e091955. doi: 10.1136/bmjopen-2024-091955.

    PubMed 40379348

Questions about this trial

What is this clinical trial studying?

An observational study of Ageing and Disability, run by Xuanwu Hospital, Beijing at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 7 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Yansu Guo, Ph.D (0086031183973736, gys188@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Disability from the individual's perspective (time frame: An average of 1 to 2 years). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06863727, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Mar 2025; AzTrials last refreshed its copy on 31 Oct 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in